IDiyas

For the Inventor, By the Inventor

Boulder, CO, United States of America

Megan L McKenney

USPTO Granted Patents = 16 

 

Average Co-Inventor Count = 14.6

ph-index = 4

Forward Citations = 45(Granted Patents)


Company Filing History:

goldMedal11 out of 329 
 
Array Biopharma Inc.
 patents
silverMedal5 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 2018-2024

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11998545 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2024-06-04),
2. 11970485 - RET kinase inhibitors (2024-04-30),
3. 11964968 - Compounds useful for inhibiting RET kinase (2024-04-23),
4. 11697647 - RET kinase inhibitors (2023-07-11),
5. 11648243 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2023-05-16),
6. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),
7. 11603374 - Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors (2023-03-14),
8. 10953005 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2021-03-23),
9. 10881652 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2021-01-05),
10. 10555944 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2020-02-11),
11. 10441581 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-10-15),
12. 10172851 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
13. 10172845 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2019-01-08),
14. 10144734 - Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors (2018-12-04),
15. 10137124 - Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors (2018-11-27),

Title: The Innovative Contributions of Megan L McKenney

Introduction

Megan L McKenney is a prominent inventor based in Boulder, Colorado, known for her significant contributions to the field of pharmaceuticals. With a total of 16 patents to her name, she has made remarkable strides in developing compounds that target critical health issues.

Latest Patents

Among her latest patents are the "Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors." These compounds are designed to inhibit RET kinase, which is crucial in treating and preventing diseases associated with RET, including various cancers. Another notable patent involves formulations containing these compounds, which are essential for developing effective treatments for RET-associated cancers.

Career Highlights

Megan has worked with leading companies in the pharmaceutical industry, including Array Biopharma Inc. and Eli Lilly and Company. Her work has been instrumental in advancing the understanding and treatment of RET-related diseases.

Collaborations

Megan has collaborated with talented individuals such as Gabrielle R Kolakowski and Steven Wade Andrews, contributing to her innovative research and development efforts.

Conclusion

Megan L McKenney's work exemplifies the impact of innovation in the pharmaceutical industry, particularly in the development of targeted therapies for cancer treatment. Her contributions continue to influence the field and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…